Holen Sie sich die Stockscreener-App
4.93
1.60%
-0.08
Schlusskurs vom Vortag:
$5.01
Offen:
$5
24-Stunden-Volumen:
8,179
Relative Volume:
0.17
Marktkapitalisierung:
$215.13M
Einnahmen:
$4.71M
Nettoeinkommen (Verlust:
$-46.77M
KGV:
-2.9359
EPS:
-1.6792
Netto-Cashflow:
$-60.34M
1W Leistung:
+9.56%
1M Leistung:
+1.02%
6M Leistung:
-36.39%
1J Leistung:
-49.54%
1-Tages-Spanne:
$5.00
$5.00
1-Wochen-Bereich:
$4.49
$5.05
52-Wochen-Spanne:
$4.345
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Vergleichen Sie NYXH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
5.00 | 215.56M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
585.12 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.14 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.23 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
251.01 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
41.98 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2021-12-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Nyxoah Sa Aktie (NYXH) Neueste Nachrichten
Is Nyxoah SA stock a good choice for value investorsSeasonal Picks & what to check before ordering - ulpravda.ru
Is Nyxoah SA stock a contrarian buyMarket Risk Summary & Free Fast Gain Swing Trade Alerts - ulpravda.ru
How Nyxoah SA (5YI) stock benefits from digital adoptionPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - ulpravda.ru
Aug Intraday: Is Nyxoah SA stock a good choice for value investors2025 Technical Overview & Community Consensus Trade Alerts - ulpravda.ru
Why Nyxoah SA stock is recommended by analysts2025 Pullback Review & Safe Entry Momentum Stock Tips - ulpravda.ru
Nyxoah receives Medicare reimbursement increases for Genio - MSN
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
PRN_FinancialWrapper | PR NewswireNyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Sleep apnea therapy developer Nyxoah joins J.P. Morgan health event - Stock Titan
Contrasting Azenta (NASDAQ:AZTA) and Nyxoah (NASDAQ:NYXH) - Defense World
Baird Maintains Nyxoah SA(NYXH.US) With Hold Rating, Cuts Target Price to $5.87 - 富途牛牛
Nyxoah SA (NYXH) Stock Analysis: Exploring a 145.53% Potential Upside in the Medical Tech Sector - DirectorsTalk Interviews
Nyxoah announces commercial launch of Genio system in the Netherlands - MSN
Nyxoah launches Genio therapy in Netherlands and closes first €22.5 million tranche of convertible notes - MSN
Nyxoah price target lowered to EUR 5 from EUR 7 at Baird - MSN
Nyxoah Announces Issuance of First Tranche of Convertible Bonds - The Manila Times
Is Nyxoah SA stock positioned for digital transformationQuarterly Trade Review & Consistent Return Investment Signals - Улправда
Nyxoah Launches Genio Therapy in Netherlands and Closes First €22.5 Million Tranche of Convertible Notes - TipRanks
Earnings Recap: Is Nyxoah SA stock a good choice for value investorsJuly 2025 Highlights & Target Return Focused Picks - moha.gov.vn
Can Nyxoah SA stock deliver strong Q4 earningsQuarterly Growth Report & Smart Swing Trading Alerts - DonanımHaber
Is Nyxoah SA (5YI) stock undervalued historicallyJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
How Nyxoah SA stock performs in high volatility markets2025 Historical Comparison & Expert Curated Trade Setups - ulpravda.ru
Nyxoah Launches New OSA Therapy | Patient-Centric Breakthrough - Precedence Research
Nyxoah Launches Genio Neurostimulator System in the Netherlands - marketscreener.com
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands - FinancialContent
Nyxoah (NASDAQ:NYXH) Trading Down 2.9%Here's What Happened - MarketBeat
Nyxoah (NASDAQ:NYXH) Trading Down 2.9% – Here’s What Happened - Defense World
Nyxoah announces shareholding changes as Robert Taub surpasses 10% threshold - MSN
Critical Analysis: Nyxoah (NASDAQ:NYXH) & P3 Health Partners (NASDAQ:PIII) - Defense World
Nyxoah Announces Shareholding Changes as Robert Taub Surpasses 10% Threshold - TipRanks
How Nyxoah SA (5YI) stock compares with tech leadersWeekly Stock Analysis & Community Verified Trade Signals - Newser
Will Nyxoah SA stock outperform international peersIPO Watch & Accurate Technical Buy Alerts - Newser
Is Nyxoah SA stock a buy for dividend growthJuly 2025 Levels & Risk Controlled Daily Plans - Newser
Will Nyxoah SA (5YI) stock remain on Wall Street radar2025 Institutional Moves & Reliable Breakout Forecasts - Newser
Nyxoah (NYXH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Publication relating to transparency notifications - marketscreener.com
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System - MSN
Can Nyxoah SA (5YI) stock sustain institutional flowsJuly 2025 Intraday Action & Daily Chart Pattern Signals - Newser
What MACD trends signal for Nyxoah SA (5YI) stock2025 Dividend Review & Verified Entry Point Signals - Newser
Nyxoah’s Genio Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Sleep Review
Why The Narrative Around Nyxoah Is Shifting Amid Fresh Developments and Analyst Caution - Yahoo Finance
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Nyxoah (NASDAQ: NYXH) schedules webcast fireside chat at Piper Sandler healthcare conference - Stock Titan
Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy - MSN
Nyxoah S.A. (NASDAQ:NYXH) Q3 2025 Earnings Call Transcript - MSN
Finanzdaten der Nyxoah Sa-Aktie (NYXH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):